Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBH589 plus melphalan, prednisone, and thalidomide in relapsed/refractory multiple myeloma
2007-007939-29Phase 2Completed
- Sponsor
- Fondazione EMN Italy
- Start
- Oct 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat, melphalan, prednisone and thalidomide in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Primary endpoints: Safety profile and Partial response rate. Started Oct 2008; status: completed.
02
Drugs
panobinostatmelphalanprednisonethalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2007-007939-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007939-29.